Review Article

Compound glycyrrhizin injection for improving liver function in children with acute icteric hepatitis: A systematic review and meta-analysis

Shi-Bing Liang a, Wen-Bin Hou a, Ruo-Xiang Zheng b, Chang-Hao Liang d, Li-Jiao Yan a, Hao-Nan Wang b, Hui-Juan Cao a, Mei Han d, Nicola Robinson c, Jian-Ping Liu b, d,∗

a Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
b School of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
c Institute of Health and Social Care, London South Bank University, London, UK
d Institute of Integrated Traditional Chinese Medicine and Western Medicine, Guangzhou Medical University, Guangzhou, China

ABSTRACT

Background: Compound glycyrrhizin injection (CGI) is a preparation with glycyrrhizin as the main active ingredient extracted from licorice. As clinical trials suggest that CGI is effective in improving liver function for acute icteric hepatitis in children (AIHC), this systematic review aimed to evaluate and verify its therapeutic effects and safety.

Methods: Six electronic databases were searched from their inception to 15 May 2021. Randomized controlled trials (RCTs) assessing therapeutic effects and safety of CGI for AIHC were included. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. Primary outcomes were indexes related to liver function, including total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate transaminase (AST). RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool.

Results: Six RCTs involving 608 children were included. The overall bias was assessed as having “high risk of bias” in all trials. All trials compared the combination of CGI and conventional western medicine (CWM) with CWM alone. Regarding the effects of CGI for AIHC, results showed that CGI plus CWM was superior to CWM alone in reducing the levels of TBIL (mean difference (MD) = 8.19 mmol/L, 95% CI -9.86 to -6.53), ALT (MD = -24.09 U/L, 95% CI -30.83 to -17.34) and AST (MD = -18.67 U/L, 95% CI -21.88 to -15.45). No trial reported adverse events. The certainty of the evidence for outcomes were all evaluated as low or very low.

Conclusion: CGI may have adjuvant therapeutic effects on improving the liver function of children with AIHC. There is no evidence to determine the safety of CGI for AIHC. As current evidence is weak, further well-designed RCTs are required for verification of the therapeutic effects of CGI.

© 2021 Korea Institute of Oriental Medicine. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Acute icteric hepatitis (AIH) is one of the clinical sub-types of acute hepatitis caused by hepatitis A, B, C, D and/or E virus, with adverse changes in bilirubin as the main characteristic.1-3 AIH develops rapidly and is highly infectious. Children are easily affected by hepatitis virus infection resulting in various adverse effects such as imperfect organ development and a poor immune system function. This can lead to the occurrence of hepatitis such as acute icteric hepatitis in children (AIHC). AIHC may lead to a variety of conditions (such as hepatic ascites, cirrhosis), if this cannot be resolved in a timely manner it can seriously affect a child's health and life.4 The main clinical symptoms of this disease include fever, hepatomegaly, and pain in the liver area. Liver function examination has shown that the levels of total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate transaminase (AST) are significantly increased.
In clinical practice, commonly used medications for the treatment of AIH include interferon, ribavirin, glutathione, etc. However, the effectiveness of these medications is often poor.\(^5\) Compound glycyrrhizin injection (CGI) is a colorless clear liquid prepared with glycyrrhizin as the main active ingredient, with glycine and cysteine hydrochloride as additional ingredients. Glycyrrhizin as a compound, is an active ingredient extracted from Gan Cao (Glycyrrhiza uralensis Fisch. ex DC.), has been reported to have various important biological activities,\(^6\) such as anti-oxidant properties, anti-cancer properties and anti-inflammatory action.\(^7\)-\(^9\) The preparation is registered in China and produced by many different companies. In Japan, glycyrrhizin injections have been used as a therapeutic drug for allergy inflammation since 1948 and for chronic hepatitis since 1979.\(^10\) By acting on multiple targets in inflammatory pathways such as phospholipase A2 and high mobility group protein 1,\(^11\),\(^12\) glycyrrhizin can inhibit the inflammatory response, reduce the pathological damage of the liver and repair damaged liver cell function\(^13\),\(^14\). Additionally, glycyrrhizin belongs to a biological macromolecule with strong polarity, so the bioavailability of injection is higher than that of oral administration.

Currently, many randomized controlled trials (RCTs) on CGI for AIH have been conducted. However, we were unable to find any systematic reviews on CGI for the treatment of AIHC, which could provide a high level of evidence to justify clinical practice. In order to further evaluate and verify the therapeutic effects and safety of CGI for children with AIHC in improving their liver function and to provide better evidence for clinical practice, a systematic review and meta-analysis was conducted.

2. Methods

2.1. Inclusion and exclusion criteria

2.1.1. Inclusion criteria

Inclusion criteria followed the PICOST (Participants, Interventions, Comparators, Outcomes, Study design, Time periods) framework. 1) Participants: Children diagnosed as AICH and infected with one or two or more of hepatitis A, B, C, D and E viruses. Age was younger than or equal to 14 years old, but no restrictions on gender or race. 2) Interventions: This could be CGI, or CGI combined with the comparator. 3) Comparators: These could be either conventional western medicine (CWM), placebo or no treatment. 4) Outcomes: Primary outcomes were indexes related to liver function, including total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate transaminase (AST).\(^15\),\(^16\) Secondary outcomes included global improvement of symptoms, the disappearance rate and duration of icterus, adverse events. For the global improvement of symptoms, these were classified into two levels: effective and ineffective. If the clinical symptoms (vomiting, fever, nausea, etc) did not improve or even deteriorated compared with before treatment, this was recorded as ineffective. Otherwise they would be called effective. The effective rate = (number of effective participants / total number of participants) × 100%. 5) Study design: Only RCT(s) were included. 6) Time periods: All lengths of treatment time and duration of follow-up were eligible. For outcomes reported at multiple time points, we used the longest reported follow-up time point.

2.1.2. Exclusion criteria

1) The full text of articles could not be obtained; 2) any duplicated articles; 3) Clinical trial protocols.

2.2. Retrieval platforms and search strategies

PubMed, Web of Science, SinoMed, China National Knowledge Infrastructure (CNKI), Wanfang Database, the China Science Technology Journal Database (VIP) were searched from their inception to August 15, 2020. The search terms include Fu Fang Gan Cao Suan Gan, Fu Fang Gan Cao Tian Su, Mei Meng, Pai Gan Neng, Gan Yan, Huang Dan, Compound Glycyrrhizin, Hepatitis, Icteric and Icterus. Search strategies for all the electronic databases can be found in Supplement-Appendix 1.

We updated the search and selected the latest published trials that met the inclusion criteria, as to May 15, 2021.

2.3. Trial selection and data extraction

Trials were selected according to the inclusion/exclusion criteria by reading the titles, abstracts and (or) full texts of the published articles.

Two authors extracted the data independently from the included trials using a pre-designed data extraction sheet, evaluated and cross-checked. The entries of extraction include article titles, authors’ information, characteristics of participants (sample size, age and disease severity, etc), details of interventions and comparators, outcomes, information relevant to trial design, etc. Any disagreements were resolved by discussions with a third author (JPL).

2.4. Risk of bias

The risk of bias of each included trial was evaluated using the Cochrane risk of bias tool 2.0\(^17\) by two authors independently. The inconsistencies were discussed with the third author (JPL). The tool consists of the following five domains: randomization process, deviations from the intended interventions, missing outcome data, measurement of the outcome and selection of the reported result. Each domain was judged as low risk of bias, high risk of bias, or some concerns.

2.5. Data synthesis

The data were synthesized descriptively, including summary statistics and detailed tables of trial characteristics.

With regard to the outcomes of CGI for AIHC, the data was pooled by conducting meta-analysis, if data allowed, by using Review Manager 5.4 (Revman 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration) software. We presented binary data as a risk ratio (RR) with its 95% confidence interval (CI), and continuous data as a mean difference (MD) with its 95% CI. The random-effects model was used for meta-analysis considering potential sources of clinical heterogeneity. If \( P < 0.10 \), this indicated that there was heterogeneity among the included trials. Meanwhile, we also referred to the value of \( I^2 \). The smaller the value of \( I^2 \), the smaller the statistical heterogeneity.\(^18\) When \( P < 0.10 \) and \( I^2 > 50\% \), the accuracy of the data was checked first. If the data was accurate, subgroup analysis based on children’ baseline, interventions and comparators and/or sensitivity analysis based on methodological quality would be conducted, if appropriate, to explore the source of heterogeneity. Otherwise, we would interpret the result carefully.

The following subgroup analyses would be conducted, according to the protocol, if appropriate: 1) Subgroup analysis based on the severity of AIHC, to detect whether the seriousness of AIHC has an impact on the effects; 2) Subgroup analysis based on the different courses of treatment, to see whether children can benefit more from long-term treatment; 3) Subgroup analysis based on medication dosage of CGI, to explore whether children can get more benefit from a high dosage.

Although planned, we did not construct funnel plots to evaluate publication bias as these are inaccurate when fewer than 10 trials are included in the analysis.\(^19\) In addition, the certainty of
the evidence for each outcome was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation criteria) approach[20] to conduct management recommendations by the GRADEpro Guideline Development Tool (GDT) online (https://gradepro.org/).

3. Results

3.1. Literature search and selection

A total of 3371 records were identified by searching electronic databases. We excluded 1840 duplicate records, and 1489 records were excluded by screening the titles and abstracts. The remaining 42 records were selected by screening full-texts, and 36 were removed for various reasons (see Fig. 1). No new randomized controlled trial was included after an updated retrieval and selection, up to May 15, 2021.

Finally, six articles (representing six individual trials[21-26]) were included in this review. Fig. 1 provides the flow diagram on the search and screening of trials.

3.2. Characteristics of included trials

Six two-armed RCTs[21-26] involving 608 participants were included in this review, all were published in Chinese. The age range of participants was 2-12 years old according to four trials[21,24-26], and the ratio of boys to girls was 1:2:1. Four trials[21-23,26] reported the types of hepatitis of the participants and the number of participants corresponding to each type of hepatitis. Participants in each of these four trials[21-23,26] involved viral hepatitis type A, viral hepatitis type B and mixed hepatitis. Only one trial[25] reported the severity of icterus, including 66 mild, 25 moderate and 3 serious cases. In all trials, the intervention was CGI plus comparator and the administration of CGI was an intravenous drip. The children in the comparator group were treated with CWM (potassium magnesium aspartate, creatinine, vitamin C and/or an energy mixture, etc). The treatment course of included trials was either 14 or 15 days duration.

The characteristics of all the included trials are summarized in Table 1.

3.3. Assessment of risk of bias

The risk of bias summary and graph of included trials is given in Fig. 2.

a) Domain 1: Risk of bias arising from the randomization process

For random sequence generation, one trial[25] used the method of random number tables, one trials[24] used lot-drawing, and the other four trials[21-23,26] only mentioned “random” or “randomization” without describing their methods in detail. For allocation concealment, no trial reported relevant information. If allocation concealment was not implemented, there is reason to suspect that the enrolling investigator or the participant had knowledge of the forthcoming allocation. Therefore, this domain for all the[21-26] included trials was judged as “some concerns” due to insufficient information.

b) Domain 2: Risk of bias due to deviations from the intended interventions

Although one[25] trial reported using a double-blind design and the other five trials[21-24,26] did not report blinding information, judged in the light of the interventions and comparators, it was impossible to blind the clinicians implementing treatments. Taking the above into consideration, deviations from the intended interventions may exist. However, all trials[21-26] did not report relevant
Table 1
Characteristics of the included studies.

| ID         | Sample size (M/F) | Age (years) | Type of hepatitis (No. of participants for each type) | Severity of disease | Intervention                                                                 | Course of treatment (days) | Outcomes |
|------------|-------------------|-------------|------------------------------------------------------|---------------------|-------------------------------------------------------------------------------|----------------------------|----------|
| Huang LL2016[21] | 36/24             | 6.9±2.4 (4-11) | A(39); B(15); Mixed(6)                             | Not reported        | 60-80ml Compound glycyrrhizin injection dissolving in 250ml 5% glucose solution, ivgtt qd (+ Comparator) | 15             | (2-3-6) |
| Wang WF2015[22]  | 27/21             | 4.5±1.4 (4-11) | A(16); B(26); Mixed(6)                             | Not reported        | 10-60ml Compound glycyrrhizin injection, ivgtt qd (+ Comparator)              | 14             | (2-3-6) |
| Liu JL2015[23]   | 22/20             | 4.7±1.6 (4-11) | A(16); B(22); Mixed(4)                             | Not reported        | 50ml Compound glycyrrhizin injection, ivgtt qd (+ comparator)                 | 14             | (2-3-6) |
| Yang M2020[25]   | 14/12             | 6.2±1.3 (3-9) | Not reported                                        | Not reported        | 60ml Compound glycyrrhizin injection dissolving in 250ml 5% glucose solution, ivgtt qd (+ Comparator) | 14             | (2-3-6) |
| Chen QJ2016[26]  | 42/39             | 2-7         | Not reported                                        | Not reported        | 20ml Compound glycyrrhizin injection, ivgtt qd (+ comparator)                 | 14             | (2-3-6) |
| Liu M2012[27]    | 53/41             | 6.8±1.4 (3-11) | A(63); B(25); Mixed(6)                             | Severity of icterus: 66(mild), 25(moderate), 3(severe) | 40-60ml Compound glycyrrhizin injection dissolving in 250ml 5% glucose solution, ivgtt qd (+ Comparator) | 14             | (2-3-6) |

A. Viral hepatitis type A; B. Viral hepatitis type B; C. Comparator group; ivgtt, intravenous drip; M, male; Mixed, mixed hepatitis; PMA, Potassium magnesium aspartate; qd, Once a day; T, Treatment (intervention) group.

Outcomes:
1. ALT, Alanine aminotransferase
2. AST, Aspartate aminotransferase
3. TBIL, Total bilirubin
4. Global improvement of symptoms
5. Duration of icterus.
information about deviations. Therefore, all trials\textsuperscript{21–26} were judged as “some concerns” in this domain.

a) \textit{Domain 3: Risk of bias due to missing outcome data}

All trials\textsuperscript{21–26} were judged as “low risk of bias” in missing outcome data domain as the probably complete, or nearly complete outcome data available.

a) \textit{Domain 4: Risk of bias in measurement of the outcome}

According to the interventions and comparators the included trials\textsuperscript{21–26} reported, all trials\textsuperscript{21–26} were impossible to blind the clinicians implementing treatments. What’s more, all trials\textsuperscript{21–26} did not report whether they blinded the outcome assessors, as well as they did not report the information of potential conflict of interest. Taking the above into consideration, all trials\textsuperscript{21–26} were judged to be of “some concerns” in measurement of the outcome.

a) \textit{Domain 5: Risk of bias in selection of the reported result}

No trial reported information on their trial protocol and registration. We could not judge whether these trials\textsuperscript{21–26} have selectively reported outcomes. Therefore, all trials\textsuperscript{21–26} were judged as “some concerns” in this domain.

According to the evaluation results of each domain, the overall bias was assessed as “high risk of bias” in all the included trials.

3.4. Outcomes

3.4.1. Primary outcomes (indexes related to liver function)

3.4.1.1. Total bilirubin (TBiL). A total of three trials\textsuperscript{22–24} reported this outcome and reported the change in TBiL levels before and after treatment. A pooled result (Fig. 3-A) showed that there was a statistical difference between the intervention and the comparator groups (MD = -8.19 mmol/L, 95% CI -9.86 to -7.53, \( P < 0.00001 \)), that is, CGI plus CWM was superior to CWM alone for AIHC in reducing the levels of TBiL.

3.4.1.2. Alanine aminotransferase (ALT). Four trials\textsuperscript{21–24} reported the change of ALT levels. Meta-analysis (Fig. 3-B) showed that CGI plus CWM might be better than CWM alone in reducing the levels of ALT and there were statistical differences (MD = -24.09 U/L, 95% CI -30.83 to -17.34, \( P < 0.00001 \)). Because of the large heterogeneity (\( I^2 = 92\% \)) between the four trials, we planned to explore the source of heterogeneity through subgroup analysis or sensitivity analysis. However, we failed to carry out relevant analyses owing
to insufficient information provided by the included trials. Nevertheless, we considered that the large heterogeneity of statistics may be related to clinical heterogeneity (e.g., disease severity, different treatment courses, different drug doses, or some other clinical practice factors).

3.4.1.3. Aspartate transaminase (AST). Four trials reported AST and all focused on the change in ALT levels before and after treatment. A result (Fig. 3-C) from the four trials showed that there was a statistical difference (MD = -18.67 U/L, 95% CI -21.88 to -15.45, \( P < 0.00001\); large statistical heterogeneity, \( I^2 = 66\%\) between intervention and comparator group, that is, CGI plus CWM may be better than CWM alone in reducing AST levels. An attempt to explore the source of large statistical heterogeneity subgroup analysis or sensitivity analysis was not possible due to the insufficient information being provided by the included trials.

3.4.2. Secondary outcomes
3.4.2.1. Global improvement of symptoms. All the included trials reported this outcome. A pooled result (Fig. 3-D) showed that there was a statistical difference between the intervention and comparator groups in improving effective rate (RR = 1.20, 95% CI 1.13 to 1.29, \( P < 0.00001\), that is, CGI plus CWM had better effects than CWM alone for AIHC on the global improvement of symptoms.

3.4.2.2. The disappearance rate or duration of icterus.

Disappearance rate of icterus No trial reported on the outcome of icterus disappearance rate.

Duration of icterus Two trials reported the duration of icterus. Of these, one trial showed that there was a statistical difference between intervention and comparator groups (MD -6.10 days, 95% CI -6.92 to -5.28, \( P < 0.00001\)), that is, CGI plus CWM was better than CWM alone in shortening the duration of icterus. The second trial reported that “the duration of icterus in the intervention group was 6.5 ± 2.1 days, which was significantly shorter than that in the comparator group”.

3.4.2.3. Adverse events. None of the included trials reported this outcome.

3.5. Subgroup analysis

Due to the low number of publications and the lack of information reported in the publications, our review was unable to conduct subgroup analyses according to the preset conditions: the severity of AIHC, the different duration of treatment and the medication dosage of CGI.

3.6. Certainty of evidence (GRADE)

Using the GRADE system recommendation approach, the certainty of the evidence for outcomes were all evaluated as low or very low. The certainty of the evidence was downgraded mainly
due to risk of bias (high risk of detection bias or reporting bias), inconsistency (significant statistical heterogeneity, or small overlap of 95% CI of different trial results). Table 2 provides a summary of the certainty of available evidence.

4. Discussion

4.1. Summary of the main findings

As mentioned earlier, one of the factors leading to AIHC is children’s imperfect organ development and low immune system function. Moreover, AIHC can also lead to further impairment of liver function in children. The results of liver function examination for children with AIHC showed that the levels of children’s total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate transaminase (AST) were significantly increased. Therefore, it is essential to improve the liver function of children with AIHC. In clinical practice, one of the important indexes for judging the improvement of liver function is whether the levels of TBIL, AST and TBIL decrease to a normal level. The results of our review demonstrated that CGI plus CWM was better than CWM alone in reducing the levels of TBIL, ALT and AST. That is, CGI may have adjuvant therapeutic effects on improving the liver function of children with AIHC.

In addition, the other treatment goals for children with AIHC are to eliminate the symptom of icterus and other symptoms (e.g., vomiting, fever, nausea). The results from one trial suggested that combining CGI with CWM was about six days shorter than for CWM alone for eliminating icterus. In terms of the global improvement of symptoms, CGI combined with CWM to treat AIHC is superior to that of CWM alone. A pooled result showed that the effective rate of global improvement of symptoms in the CGI group was 94.08% (286/304), which was approximately 17% higher than that of the control group (76.64%, 233/304), and was similar to the effective rate of all trials reporting this outcome (92.31% to 95.74%).

In conclusion, the use of CGI plus CWM in the treatment of AIHC may be an effective choice.

4.2. Implications for the clinical practice

All the interventions in the included trials compared CGI with CGI plus CWM. There were no trials included that examined the use of CGI alone to treat AIHC. The evidence in this review indicated that CGI may have adjuvant therapeutic effects on the treatment of children with AIHC. Therefore, we suggest that CGI, combined with CWM, could be useful in the treatment of AIHC. The CWM includes potassium magnesium aspartate, creatinine, vitamin C and/or energy mixtures, etc. However, whether CGI alone can be used to treat AIHC needs further study in the future.

The course of treatment for all the included studies was either 14 or 15 days duration. Therefore, we suggest that CGI could be used for at least 14 days in clinical practice. It is unclear whether a more prolonged use of CGI will provide greater benefit to children. Safety of long term use also requires investigation. The dose of CGI ranged from 10 to 80 ml in light of the characteristics of the included trials. However, we failed to perform a subgroup analysis for different doses as planned, so the optimum number of doses to provide most benefit still needs clarification and is worthy of further exploration.

4.3. Strengths and limitations

This is the first systematic review, as far as we know, related to RCTs on the therapeutic effects and safety of CGI for AIHC. This review provides better evidence for clinical practice to further evaluate and verify the therapeutic effects of CGI for children with AIHC in improving their liver function. There are also limitations. No trial with low risk of bias was included and the sample sizes were small in the included trials and safety data was lacking.

4.4. Suggestions and implications for future research

According to the problems identified in the included RCTs, the following suggestions are proposed for future relevant RCTs.

(a) Use of an appropriate random allocation method (e.g., random number tables), with detailed reporting. In addition, the randomization should be properly concealed when participants are randomly assigned (e.g., numbered and light-tight sealed envelopes) to ensure the effective implementation of randomization.

(b) Ensure blinding of participants, physicians, outcome assessors and data analysts. The aims of blinding are to remove bias (per-
formance bias and detection bias).27–29 For instance, participants and those evaluating the data from the trial do not have a preference for one treatment above another.28

(c) Use of the appropriate method to estimate the sample size of participants to ensure the reliability and validity of the study results.30

(d) Development of a detailed study protocol which is registered on the relevant website in advance. Related websites include clinicaltrials.gov (www.clinicaltrials.gov), Chinese ClinicalTrials Registry (ChiCTR, www.chictr.org.cn), and etc. The study protocol can be developed with reference to the SPIRIT 2013 Statement: Defining standard protocol items for clinical trials.31,32 Meanwhile, it is suggested that a standardized report should be formulated with reference to the Consolidated Standards of Reporting Trials (CONSORT) statement.13

(e) The last and most important issue is about the safety of medication for children. As children are a special population, attention to the safety of children’s medication is critical. However, according to the reports of outcomes in the included RCTs, the safety of CG1 in the treatment of AIHC has not been given enough attention. Therefore, it is suggested that the safety of CG1 used in AIHC should be evaluated and reported in the future.

4.5. Conclusion

Low or very low certainty evidence demonstrated that CG1 has apparent adjuvant therapeutic effects on improving the liver function of children with AIHC. CG1 plus CWM was better than CWM alone in reducing the levels of TBIL, ALT and AST, on the global improvement of symptoms and in shortening the duration of icterus. There was no evidence to determine the safety of CG1 for AIHC.

As current evidence is weak, further well-designed RCTs are required for verification of the therapeutic effects of CG1.

Acknowledgements

We greatly thank the following people: Lei-Ming Xi from the First Affiliated Hospital of Shandong University of TCM, Tian-Yuan Wen from the Shandong University of Chinese Medicine, Jie Tan from the Second Affiliated Hospital of Shandong University of TCM, Yang Yang and Xiao-Lan Su from Wangjing Hospital of CACMS, for their guidance on expertise related to acute icteric hepatitis in children; the editors and reviewers for their feedback and comments on this paper; Ying-Ying Zhang and Ying-Jie Guan from Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, for their help in the revision of this paper.

Note: Acknowledgements are developed with the explicit statement that this does not constitute endorsement of the report.

Author contributions

Conceptualization: JPL and SBL; Methodology: JPL, SBL and HJC; Software: SBL and WBH; Formal Analysis: SBL, WBH and HJC; Resources: SBL, WBH and CHL; Data Curation: SBL, WBH and HNW; Writing – Original Draft: SBL; Writing – Review & Editing: RXZ, LJY, HJC, MH, NR and JPL; Supervision: JPL; Project Administration: JPL and SBL; Funding Acquisition: JPL and NR. All authors have read and approved the manuscript, including the authorship list.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

Prof. Jian-Ping Liu is supported by the National Natural Science Foundation project (No. 81830115) in China. Prof. Nicola Robinson (visiting Professor of Beijing University of Chinese Medicine) is funded by the Project of International Development and Capability Improvement of Evidence-based Chinese Medicine (G20200001187).

Ethical statement

This work did not require an ethical approval as it does not involve any human or animal experiment.

Data availability

The data used in this study are included in the article.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.imr.2021.100772.

References

1. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009 May;49(5 Suppl):S13–S21. doi: 10.1002/hep.22881.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S21–S29. doi: 10.1053/jhep.2002.03227.
3. Wang YF, Xu WT. Effects of a molecular weight heparin sodium combined with compound glycyrrhizin in the treatment of acute icteric hepatitis E. J Suzhou Univ. 2009;29(05):965–966.
4. Xiang ZX, Tan CR. Comparison of clinical efficacy of Shuganning injection and ornithine aspartate injection on improving pediatric icteric hepatitis. Chin J Woman Child Health Res. 2017;28(04):408–411.
5. Liu CH. Guidelines for diagnosis and treatment of acute and chronic liver diseases [C]. Chin soc TCM. Collection of papers of the 13th Academic Conference on hepatobiliary diseases of the Chinese society of TCM; 2008:13.
6. Jiang RH, Xu JJ, Zhu DC, Li JF, Zhang CX, Lin N. Glycyrrhizin inhibits osteoarthritis development through suppressing the P38/AKT/NF-kB signaling pathway in vivo and in vitro. Food Funct. 2020 Mar 1;11(3):2126–2136. doi: 10.1039/c9fo02241d.
7. Li XL, Zhou AG, Zhang L, Chen WJ. Antioxidant status and immune activity of glycyrrhizin in allergic rhinitis mice. Int J Mol Sci. 2011 Jan;12(2):905–916. doi: 10.3390/ijms12020905.
8. Rakcóvá L, Jancinová V, Petříková M, Dráblíková K, Nosář R, Stefek M. Mechanism of anti-inflammatory action of liquorice extract and glycyrrhizin. Nat Prod Res. 2007 Dec;21(14):1234–1241. doi: 10.1080/14786410701371280.
9. Kim KJ, Choi JS, Kim KW, Jeong JW. The anti-angiogenic activities of glycyrrhizin acid in tumor progression. Phytother Res. 2013 Jun;27(6):841–846. doi: 10.1002/ptr.4800.
10. Koga K, Kawashima S, Shibata N, Takada K. Novel formulations of a liver protection drug glycyrrhizin. Yakugaku Zasshi. 2007 Jul;127(7):1103–1114 Japanese. doi: 10.1248/yakuz.127.1103.
11. Andersson U, Tracey KJ. HMGCR1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162. doi: 10.1146/annurev-immunol-030409-101323.
12. Mahmoud AM, Al Dera HS. 18β-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of FPR1R and Nr2 upregulation. Genes Nutr. 2015 Nov;10(6):41. doi: 10.1007/s11039-015-0491-1.
13. Expert committee on clinical application of glycyrrhizin preparation in the treatment of liver diseases. J Clin Hepat. 2016;32(05):844–852.
14. Zhao YK, Li L, Liu X, Cheng SF, Gao QQ, Fan DP. Explore pharmacological mechanism of glycyrrhizin based on systems pharmacology. Zhongguo Zhong Yao Za Zhi. 2016 May;41(10):1916–1920 Chinese. doi: 10.4628/cjcm201601026.
15. Zhang P. Modern pediatrics. Beijing: People’s Medical Pub; 1998:395–407.
16. Shen XM. Clinical pediatrics. Beijing: People’s Health Pub House; 2005:1059.
17. Sterne JAC, Savovíc J, Page MJ, Roberts R: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug;366:l4898. doi: 10.1136/bmj.l4898.
18. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Clarke handbook for systematic reviews of interventions version 5.1 (updated September 2020). Cochrane. 2020. Available from: www.training.cochrane.org/handbook
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.
20. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008 May 3:330(7518):995–998. doi: 10.1136/bmj.39490.551019.BE.
21. Huang LL. Observation on the therapeutic effect of compound glycyrrhizin for 120 children with acute icteric hepatitis. Clin Study. 2016;24(2):26–27.

22. Wang WF. Analysis of curative effect of compound glycyrrhizin injection in adjuvant treatment of children with acute icteric hepatitis. Mod Chin Med Appl. 2015;3(20):136–137. doi:10.14164/j.cnki.cn11-5581/i.2015.20.106.

23. Liu JL. Effect of compound glycyrrhizin injection on adjuvant treatment of acute icteric hepatitis in children. Fam Psychol. 2015;011(002) 247–247.

24. Yang M. Analysis of curative effect of compound glycyrrhizin injection in adjuvant treatment of children with acute icteric hepatitis. Smart health. 2020;6(15):112–113. doi:10.19335/j.cnki.2096–1219.2020.15.054.

25. Chen QJ. Clinical analysis of treating 162 children with acute icteric hepatitis. Chin Med Eng. 2016;24(5):305–310. doi:10.3933/j.issn.1004–0412.2012.05.047.

26. Liu M. Observation on the effect of compound glycyrrhizin in the treatment of 47 children with acute icteric hepatitis. Jilin Med. 2012;33(28) 6120–6120. doi:10.3969/j.issn.1004–0412.2012.05.047.

27. Wang LQ, Li Q, Su CX, Liu JP. Application and evaluation of blind method in randomize controlled trials of Chinese medicine. J Tradit Chin Med. 2014;55(1):28–33.

28. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol. 2012 Apr;140(3):550–554. doi:10.1016/j.ejphar.2011.12.017.

29. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Muir K, Yu H, GP-TCM etc. Unabridged guidelines for randomised controlled trials investigating Chinese herbal medicine (CHM). Eur J Integr Med. 2014 http://dx.doi.org/10.1016/j.eujim.2013.07.011.

30. Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012 Jan;5(1):7–13. doi:10.4103/0974–1208.97779.

31. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleža-Jerić K. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200–207. doi:10.7326/0003-4819-158-3-201302050-00013.

32. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi:10.1136/bmj.e7586.

33. Schulz KF, Altman DG, Moher D. Group CONSORT. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar;340:c332. doi:10.1136/bmj.c332.